Vamikibart in Participants With Uveitic Macular Edema

Summary

This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.

Timeline

Start

2023-03-23

Primary completion

2025-05-07

Completion

2025-12-24

Outcome

Missed primary endpoint

release “primary endpoint data demonstrating statistically significant superiority over sham in MEERKAT, though not in SANDCAT” gene.com ↗

Drugs

Indications